"As the team responsible for EMD Serono's compliance oversight we look forward to implementing the revised Code, continuing our strong compliance training programs for employees and are very pleased to have participated in the development of the new Code," said Robert Freeman, Chief Compliance Officer of EMD Serono, Inc. "It remains paramount to our organization that our interactions with healthcare professionals meet the highest ethical standards while delivering valuable information to healthcare professionals and patients."
EMD Serono is one of a few biopharmaceutical companies with US headquarters in the state of Massachusetts that is a member of PhRMA. EMD Serono remains a leader in conducting ethical interactions with healthcare providers to ensure patients can obtain the products necessary to treat their illnesses appropriately.
Additional information on the revised code can be seen at http://www.phrma.org
About EMD Serono, Inc.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a
leader in the US biopharmaceutical arena, integrating cutting-edge science
with unparalleled patient support systems to improve people's lives. The
company has strong market positions in neurodegenerative diseases, with
Rebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R)
(somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNA
origin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) for
injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R)
(follitropin alpha for injection), Luveris(R) (lutropin alfa for injection)
|SOURCE EMD Serono, Inc.|
Copyright©2008 PR Newswire.
All rights reserved